Home
Sanofi and AstraZeneca: Nirsevimab Protects Healthy Pre-Term and Term Infants from Respiratory Syncytial Virus

Sanofi and AstraZeneca: Nirsevimab Protects Healthy Pre-Term and Term Infants from Respiratory Syncytial Virus

Impacting News April 27, 2021

Sanofi and AstraZeneca MELODY Trial Results for Nirsevimab
In March 2017, Sanofi (SNY) and AstraZeneca (This content is for paid subscribers.

Please click here to subscribe or here to log in.
Impacting News
,
April 27, 2021

Other Articles